| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pediatrics and the Immunology Program, Stanford University School of Medicine, Stanford, CA 94305;
Department of Molecular Biology, Immunex Corporation, Seattle, WA 98101; and Departments of
Medicine and
§
Comparative Medicine, University of Washington, Seattle, WA 98195
Allergen-induced asthma is characterized by chronic pulmonary inflammation, reversible bronchoconstriction, and airway hyperreactivity to provocative stimuli. Multiple CC-chemokines, which are produced by pulmonary tissue in response to local allergen challenge of asthmatic patients or experimentally sensitized rodents, chemoattract leukocytes from the circulation into the lung parenchyma and airway, and may also modify nonchemotactic function. To determine the therapeutic potential of local intrapulmonary CC-chemokine blockade to modify asthma, a recombinant poxvirus-derived viral CC-chemokine inhibitor protein (vCCI), which binds with high affinity to rodent and human CC-chemokines in vitro and neutralizes their biological activity, was administered by the intranasal route. Administration of vCCI to the respiratory tract resulted in dramatically improved pulmonary physiological function and decreased inflammation of the airway and the lung parenchyma. In contrast, vCCI had no significant effect on the circulating levels of total or allergen-specific IgE, allergen-specific cytokine production by peripheral lymph node T cells, or peritoneal inflammation after local allergen challenge, indicating that vCCI did not alter systemic Ag-specific immunity or chemoattraction at extrapulmonary sites. Together, these findings emphasize the importance of intrapulmonary CC-chemokines in the pathogenesis of asthma, and the therapeutic potential of generic and local CC-chemokine blockade for this and other chronic diseases in which CC-chemokines are locally produced.
This article has been cited by other articles:
|
|
 |
|
  Z. Lateef, M. A. Baird, L. M. Wise, A. A. Mercer, and S. B. Fleming Orf virus-encoded chemokine-binding protein is a potent inhibitor of inflammatory monocyte recruitment in a mouse skin model J. Gen. Virol., June 1, 2009; 90(6): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tliba, Y. Amrani, and R. A. Panettieri Jr Is Airway Smooth Muscle the "Missing Link" Modulating Airway Inflammation in Asthma? Chest, January 1, 2008; 133(1): 236 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, M. DeRider, M. A. McCornack, S.-c. Jao, N. Isern, T. Ness, R. Moyer, and P. J. LiWang Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta PNAS, September 19, 2006; 103(38): 13985 - 13990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Arnold and D. H. Fremont Structural determinants of chemokine binding by an ectromelia virus-encoded decoy receptor. J. Virol., August 1, 2006; 80(15): 7439 - 7449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lucas and G. McFadden Secreted Immunomodulatory Viral Proteins as Novel Biotherapeutics J. Immunol., October 15, 2004; 173(8): 4765 - 4774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Spinetti, M. Wang, R. Monticone, J. Zhang, D. Zhao, and E. G. Lakatta Rat Aortic MCP-1 and Its Receptor CCR2 Increase With Age and Alter Vascular Smooth Muscle Cell Function Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1397 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Penido, A. Vieira-de-Abreu, M. T. Bozza, H. C. Castro-Faria-Neto, and P. T. Bozza Role of Monocyte Chemotactic Protein-1/CC Chemokine Ligand 2 on {gamma}{delta} T Lymphocyte Trafficking during Inflammation Induced by Lipopolysaccharide or Mycobacterium bovis Bacille Calmette-Guerin J. Immunol., December 15, 2003; 171(12): 6788 - 6794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Seet, C. A. McCaughan, T. M. Handel, A. Mercer, C. Brunetti, G. McFadden, and S. B. Fleming Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors PNAS, December 9, 2003; 100(25): 15137 - 15142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Johnston and G. McFadden Poxvirus Immunomodulatory Strategies: Current Perspectives J. Virol., June 1, 2003; 77(11): 6093 - 6100. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Reading, J. A. Symons, and G. L. Smith A Soluble Chemokine-Binding Protein from Vaccinia Virus Reduces Virus Virulence and the Inflammatory Response to Infection J. Immunol., February 1, 2003; 170(3): 1435 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Seet and G. McFadden Viral chemokine-binding proteins J. Leukoc. Biol., July 1, 2002; 72(1): 24 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dabbagh, M. E. Dahl, P. Stepick-Biek, and D. B. Lewis Toll-Like Receptor 4 Is Required for Optimal Development of Th2 Immune Responses: Role of Dendritic Cells J. Immunol., May 1, 2002; 168(9): 4524 - 4530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Lilly and B. L. Daugherty A Novel LPS-Inducible CCR3 Activator . Why So Many CCR3 Ligands? Am. J. Respir. Cell Mol. Biol., December 1, 2001; 25(6): 673 - 675. [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Beck, C. Studer, J.-F. Zuber, B. J. Demange, U. Manning, and R. Urfer The Viral CC Chemokine-binding Protein vCCI Inhibits Monocyte Chemoattractant Protein-1 Activity by Masking Its CCR2B-binding Site J. Biol. Chem., November 9, 2001; 276(46): 43270 - 43276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Seet, J. Barrett, J. Robichaud, B. Shilton, R. Singh, and G. McFadden Glycosaminoglycan Binding Properties of the Myxoma Virus CC-chemokine Inhibitor, M-T1 J. Biol. Chem., August 3, 2001; 276(32): 30504 - 30513. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
